Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
50 hedge funds and large institutions have $30.2M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 17 closing their positions.
19% less funds holding
Funds holding: 62 → 50 (-12)
24% less capital invested
Capital invested by funds: $39.8M → $30.2M (-$9.55M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
+$1.87M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.13M |
| 3 |
Renaissance Technologies
New York
|
+$661K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$148K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.75M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$1.14M |
| 3 |
SG Americas Securities
New York
|
-$750K |
| 4 |
EP
Eversept Partners
New York
|
-$299K |
| 5 |
HCA
Harbor Capital Advisors
Chicago,
Illinois
|
-$168K |
ORTX Hedge Fund Activity: Q2 2022 in Review
50 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q2 2022, worth a combined $30.2M — down 24% from $39.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ORTX and 7 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Temasek Holdings, adding an estimated $1.87M. The largest seller was RA Capital Management, cutting an estimated $3.75M.
- 50 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q2 2022, down from 62 in Q1 2022.
- Funds reported $30.2M of Orchard Therapeutics plc American Depositary Shares stock for Q2 2022, down 24% quarter-over-quarter.
- 7 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q2 2022 and 17 closed out, a net change of -10 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q2 2022 was Temasek Holdings, an estimated $1.87M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q2 2022 was RA Capital Management, an estimated $3.75M sold.
Based on aggregated 13F filings for Q2 2022.